Foot Disease Management by General Practitioners in People With and Without Diabetes: An Analysis of Nationally Representative Primary Care Data in Australia
Australian GP management rates for foot disease are higher than many more well-known health conditions and increasing. GPs frequently manage foot disease with medications and procedures, but relatively rarely counsel or refer. Future strategies to improve GP foot disease management and referrals are needed.
Authors
- Christopher Harrison (ORCID: https://orcid.org/0000-0002-8769-6877)
- Julie Gordon (ORCID: https://orcid.org/0000-0002-3136-5323)
- Cylie Williams (ORCID: https://orcid.org/0000-0002-0223-9141)
- Hylton B. Menz (ORCID: https://orcid.org/0000-0002-2045-3846)
- Susanna Cramb (ORCID: https://orcid.org/0000-0001-9041-9531)
- Peter A Lazzarini (ORCID: https://orcid.org/0000-0002-8235-7964)
Institutions
- The University of Sydney (AU)
- Queensland University of Technology (AU)
- La Trobe University (AU)
- Menzies School of Health Research (AU)
- Metro South Health (AU)
- Monash Health (AU)
- Prince Charles Hospital (AU)
- Sydney Local Health District (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Foot and Ankle Research
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1002/jfa2.70066
- Primary Topic
- Diabetic Foot Ulcer Assessment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Bayer
- Roche
- Sanofi
- Wyeth
- AbbVie
- Australian Government
- Department of Veterans' Affairs, Australian Government
- Pfizer Australia
- GlaxoSmithKline Australia
- Queensland University of Technology
- Department of Health and Aged Care, Australian Government
- AstraZeneca Australia
- Sanofi Australia
- Novartis Australia
- MSD Australia
- Medical Research Council
- National Health and Medical Research Council
- Cilag